This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Fusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting FPI-2068, a Novel Targeted Alpha Therapy for EGFR-cMET Expressing Cancers

PR Newswire - Thu Oct 12, 2023

Data presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

FPI-2068 demonstrates anti-tumor activity in colorectal and lung tumor xenograft mouse models

Read more at prnewswire.com